PTGES and cancer: MAPEGs are considered promising drug targets,[4, 5] indeed, mPGES‐1 inhibitors are proposed as alternatives to NSAIDs.[6, 7] The latters, by suppressing PGs formation through COX‐1/2 inhibition, increase LT production giving rise to side effects.[8] In this context, multitargeting strategies[9, 10] for concurrent inhibition of PGE2 and LT biosynthesis, based on inhibitors[11, 12] blocking related proteins, are particularly pursued for development of safer therapeutical treatment of inflammation and cancer.